Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma

Authors

  • Jun Teishima
  • Takuro Hara Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Taisuke Tobe Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Junichiro Hirata Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Hideto Ueki Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Naoto Wakita Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Yusuke Shiraishi Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Yasuyoshi Okamura Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Yukari Bando Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Tomoaki Terakawa Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Junya Furukawa Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Ken-ichi Harada Department of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
  • Yuzo Nakano Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan
  • Masato Fujisawa Department of Surgery, Division of Urology, Kobe University, Graduate School of Medicine, Kobe, Japan

DOI:

https://doi.org/10.5489/cuaj.8548

Keywords:

metastatic renal cell carcinoma, combination therapy, immune checkpoint inhibitor, non-clear cell renal cell carcinoma

Abstract

INTRODUCTION: We aimed to clarify the therapeutic outcome of combination therapy using immune-checkpoint inhibitors (ICIs) and/or tyrosine kinase inhibitors (TKIs) for metastatic non-clear-cell renal cell carcinoma (nccRCC).

METHODS: We have been retrospectively investigating the therapeutic efficacy and prognosis in 36 patients with metastatic nccRCC undergoing combination therapy using two ICIs, ipilimumab plus nivolumab (ICI-ICI), and ICI plus TKI (ICI-TKI), at Kobe University and affiliated institutions since 2018. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse event (AE) were compared.

RESULTS: The first-line regimen was ICI-ICI in 26 cases and ICI-TKI in 10 cases. The ORRs in the ICI-ICI and ICI-TKI groups were 34.6 and 30.0%, respectively (p=0.9433). The 50% PFS for the ICI-TKI group was 9.7 months, significantly longer than that for the ICI-ICI group (4.6 months, p=0.0499), and there was no significant difference in OS between groups (p=0.3984). There was no significant difference in the occurrence rate of AE for below grade 2 (p=0.8535), nor above grade 3 (p=0.3786) between the ICI-ICI and ICI-TKI groups.

CONCLUSIONS: From our analysis of real-world data, a better outcome of PFS was expected in the ICI-TKI group compared with that in the ICI-ICI group, while there was no significant difference in OS or ORR.

Downloads

Download data is not yet available.

Author Biography

Jun Teishima

Downloads

Published

2024-01-30

How to Cite

Teishima, J., Hara, T., Tobe, T., Hirata, J., Ueki, H., Wakita, N., Shiraishi, Y., Okamura, Y., Bando, Y., Terakawa, T., Furukawa, J., Harada, K.- ichi, Nakano, Y., & Fujisawa, M. (2024). Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma . Canadian Urological Association Journal, 18(5), E162–6. https://doi.org/10.5489/cuaj.8548

Issue

Vol. 18 No. 5 (2024): CUAJ May

Section

Original Research

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.